Multidrug Resistance Protein 2 Implicates Anticancer Drug-Resistance to Sorafenib

Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation

(2010) J. S. Lagas et al.   MOLECULAR CANCER THERAPEUTICS

Nilotinib (AMN107, Tasigna ® ) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters

(2009) Amit K. Tiwari et al.   BIOCHEMICAL PHARMACOLOGY

Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib

(2009) Kaja Zimmermann et al.   ONCOLOGY

Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2

(2008) S. Shukla et al.   DRUG METABOLISM AND DISPOSITION

Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis

(2008) Christian Eichelberg et al.   EUROPEAN UROLOGY

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

(2008) S. Marchetti et al.   MOLECULAR CANCER THERAPEUTICS

Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies

(2008) T. E. Hutson et al.   ONCOLOGIST